Niveau de preuve du suivi therapeutique pharmacologique de l’atazanavir

Molla, 1996, Ordered accumulation of mutations in HIV protease confers resistance to ritonavir, Nat Med, 2, 760, 10.1038/nm0796-760 Le Guellec, 2009, Méthodologie pour l’évaluation du niveau de preuve du suivi thérapeutique pharmacologique, La Lettre du Pharmacologue, 23, 29 Yeni, 2008 Busti, 2004, Atazanavir for the treatment of human immunodeficiency virus infection, Pharmacotherapy, 24, 1732, 10.1592/phco.24.17.1732.52347 http://packageinserts.bms.com/pi/pi_reyataz.pdf. Bertz, 2007 Pellegrin, 2006, Virological responses to atazanavirritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study), Antivir Ther, 11, 421, 10.1177/135965350601100407 Cleijsen, 2007, Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice, J AntimicrobChemother, 60, 897 Solas, 2008, The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients, J Acquir Immune Defic Syndr, 48, 177, 10.1097/QAI.0b013e318164226a Zhu, 2008 Zhang, 2005, In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation, Drug Metab Dispos, 33, 1729, 10.1124/dmd.105.005447 Barrios, 2004, Predictors of virologic response to atazanavir in protease inhibitor-experienced patients, HIV Clin Trials, 5, 201, 10.1310/3HL3-HHBD-WKLR-XELL Smith, 2006, Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations, HIV Clin Trials, 7, 34, 10.1310/0KX0-H9VH-99EE-5D0L Gonzalez de Requena, 2005 Ray, 2005, Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic, Br J Clin Pharmacol, 60, 291, 10.1111/j.1365-2125.2005.02413.x Rodríguez Nóvoa, 2006, Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C–> T polymorphism at the multidrug resistance gene 1, Clin Infectious Dis, 42, 291, 10.1086/499056 Colombo, 2006, Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection, Antimicrob Agents Chemother, 50, 3801, 10.1128/AAC.00098-06 Solas, 2008, Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients, Ther Drug Monit, 30, 670, 10.1097/FTD.0b013e3181897bff Perloff, 2005, Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro, Drug Metab Dispos, 33, 764, 10.1124/dmd.104.002931 Croom, 2009, Atazanavir: a review of its use in management of HIV-1 infection, Drugs, 69, 1107, 10.2165/00003495-200969080-00009 Luber, 2007, Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20mg omeprazole in healthy volunteers, HIV Med, 8, 457, 10.1111/j.1468-1293.2007.00496.x Tomilo, 2006, Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers, Pharmacotherapy, 26, 341, 10.1592/phco.26.3.341 Taburet, 2004, Interactions between atazanavirritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients, Antimicrob Agents Chemother, 48, 2091, 10.1128/AAC.48.6.2091-2096.2004 von Hentig, 2007, Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults, Eur J Clin Pharmacol, 63, 935, 10.1007/s00228-007-0344-y Calcagno, 2009, Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting, J Acquir Immune Defic Syndr, 52, 431, 10.1097/QAI.0b013e3181b08f09 Rodríguez Nóvoa, 2007, Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia, AIDS, 21, 41, 10.1097/QAD.0b013e328011d7c1 Stöhr, 2010, Factors influencing lopinavir and atazanavir plasma concentration, J Antimicrob Chemother, 65, 129, 10.1093/jac/dkp408 Molto, 2007, Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice, Ther Drug Monit, 29, 648, 10.1097/FTD.0b013e31815704c1 Rodriguez-Novoa, 2008, Switch from ritonavirboosted to unboosted atazanavir guided by therapeutic drug monitoring, AIDS Res Hum Retroviruses, 24, 821, 10.1089/aid.2007.0276